Marc A. Silver, MD, FACP, FACC, FCCP, FAHA, FHFSA
Dr. Marc A. Silver served as the Chief, Division of Medical Services, Chairman of the Department of Medicine, and was the Founder of the Heart Failure Institute at Advocate Christ Medical Center in Oak Lawn, Illinois from 1998 to 2018. He is an international leader in heart failure, a founding member of the Heart Failure Society of America, author of HFSA and ACC/AHA heart failure guidelines for over a decade, and served as Editor-in-Chief of Congestive Heart Failure for 15 years.
Throughout his career, his focus has been to optimize care and outcomes for patients, families, provider teams, and health systems.
John L. Jefferies, MD, MPH, FACC, FAHA, FAAP, FHFSA, FESC, FRCPE
Dr. John L. Jefferies is the Jay Michael Sullivan Endowed Chair in Cardiovascular Medicine at the University of Tennessee Health Science Center. He has 20 years of experience in adult cardiovascular disease and pediatric cardiology focusing on advanced heart failure, cardiomyopathies, cardio-oncology, and genetically triggered disease. He is an internationally recognized leader with over 250 peer-reviewed publications. He is the Co-Editor of two leading textbooks and serves on multiple leadership committees. He is the current Governor of the Tennessee Chapter of the American College of Cardiology and the President of American Heart Association Mid-South region.
Throughout his career, John has focused on improving the lives of children and adults with cardiovascular disease through research, education, clinical care, and advocacy.
Cynthia A. Stavish, MSN, APRN, ACNS-BC, PHN
Cynthia A. Stavish has 30 years of critical care nursing experience including trauma ICU, cardiovascular ICU, solid organ transplant, medical ICU, surgical ICU, and emergency nursing. She is an expert in the care of the complicated critically ill patient, acute decompensated heart failure, pain and sedation management in the mechanically ventilated patient, delirium identification and clinical management, cardiac, lung, and liver transplant, ARDS, and septic shock. She has co-authored numerous research articles and has written and presented numerous educational programs.
Throughout her career, Cynthia has focused on evidence-based care and improved quality of life following critical illness.
Robin E. Traufler, MN, APRN-BC, ACNP
Robin is an acute care nurse practitioner with 25 years of experience. Her clinical experience as a nurse practitioner includes nephrology and over 17 years in cardiology with the last 7 years specializing in patients with advanced heart failure. She received her Master’s in Nursing from the University of South Carolina. Robin has served on numerous committees including the SC Nurses Association and the HFSA Education committee and has presented at key conferences including the ACC.
Robin’s passion throughout her career has been delivering patient-centered care to improve their quality of life and outcomes.
Megan Boggs, RN, BSN
Megan Boggs is a registered nurse with experience in chronic cardiac illnesses including heart failure, hypertension and atrial fibrillation. As a clinical nurse, she provided direct patient care and education, trained staff on new technologies, and held an active role as a charge nurse for a 28-bed unit. Megan holds a BSN from LaSalle University.
Megan’s passion is to serve the heart failure community through innovation and education.
What is the BVA-100 Test?
The BVA-100 is an FDA-cleared diagnostic test approved to:
- Measure intravascular total blood volume, red blood cell volume and plasma volume
- Calculate patient-specific ideal volumes based on height, weight and gender
- Quantify the percent deviation from the predicted ideal normal value in milliliters and as a percentage expressing whether the patient has normal, expanded or depleted volumes
- Report the albumin transudation rate as an indicator of capillary permeability
Dozens of published peer-reviewed studies across many medical conditions have proven the BVA-100’s unique safety, accuracy, efficacy, and value. Accurate quantification of total blood volume, plasma volume, and red blood cell volume analysis informs physicians leading to better treatment strategies and better patient outcomes.
Partner With the Dedicated Leader in BVA
As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.
Volume is Vital. End the Debate With Daxor.
Call us at 865-425-0555.
Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.
Daxor Corporation – 107 Meco Lane, Oak Ridge, TN 37830
Phone: 865-425-0555 | Fax: 865-425-0551
firstname.lastname@example.org | daxor.com
ISO 13485 Certified
Made in the USA.
COPYRIGHT 2023 © DAXOR CORPORATION – ALL RIGHTS RESERVED.